In the Phase 2 study evaluating berzosertib with gemcitabine and cisplatin, cytopenias led to patients receiving lower cumulative doses of cisplatin, likely compromising efficacy in bladder cancer.30 Therefore, future studies will need to consider these DLTs when combining agents with ATR inhibitors. Here, ATR is linked to urinary bladder carcinoma.